Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• AMPK 0
• JNK 0
• PTEN 1
• YAP 0
• MYC 0
• GPX4 0
• NRAS 8
• IL-6 0
• MET 7
• JAK 0
• PARP 1
• CXCR4 0
• NLRP3 0
• TNF 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• MEK 1
• CDK4/6 2
• CD47 1
• BRCA1 1
• FGFR 0
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 4,665 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Cryptosporidium Infection and Human Colorectal Cancer

  NCT04332705· Lille Catholic University· Updated 6 Nov 2026

  “No other patients could be included within the time frame.”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

  NCT05629442· Massachusetts General Hospital· Updated 4 Nov 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  NCT05985109· Peking University Cancer Hospital & Institute· Updated 3 Nov 2026

  “The study was stopped early due to lack of efficacy.”Registry text, quoted unchanged. Source

• Suspended

  Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

  NCT07011550· M.D. Anderson Cancer Center· Updated 2 Nov 2026

  “PI Request”Registry text, quoted unchanged. Source

• Suspended

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Updated 28 Oct 2026

  “Protocol is with FDA review, waiting for funding to be released”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Terminated

  The Impact of Laparotomy and Analgesia Methods on Diaphragm

  NCT06403540· Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization· Updated 22 Oct 2026

  “The study was terminated prematurely because the planned sample size could not be achieved due to insufficient participant recruitment.”Registry text, quoted unchanged. Source

• Suspended

  EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden

  NCT04840186· Oslo University Hospital· Updated 22 Oct 2026

  “Not enough patients”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Pfizer· Source

• SCREEN Yourself for Cancer

  NCT07927686· Milton S. Hershey Medical Center· Source

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

  NCT07715903· National Cancer Institute (NCI)· Source

• Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

  NCT06149481· National Cancer Institute (NCI)· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  NCT04222413· National Cancer Institute (NCI)· Source

• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

  NCT04847063· National Cancer Institute (NCI)· Source

• Collection of Blood From Patients With Cancer

  NCT00034216· National Cancer Institute (NCI)· Source

• Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

  NCT06102902· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 335
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 21
• Exome Sequencing 26
• Proteomics 106
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 209
• Deep Learning 142
• Cohort Studies 315
• Genome-Wide Association Study 65

• Vascular Proliferation Index Via a Single-Cell Analysis Is a Superior Prognostic Biomarker to Microvessel Density in Stage II/III Colorectal Cancer.

  Anticancer Res, Oct 2026

• A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.

  J Vis Exp, Sept 2026

• Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas.

  Eur J Cancer, Aug 2026

• Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue.

  Cytometry A, Jun 2026

• Cytometry by Time-of-Flight for Profiling Therapeutic Response in Colorectal Cancer: Strengths, Limitations, and Translational Challenges.

  Anticancer Res, May 2026

• Perforin and Granulysin-Mediated Cytotoxicity in Colorectal Cancer Patients.

  Medicina (Kaunas), Apr 2026

• Bridging Target Recognition with Direct Molecular Counting: A DNA Framework Converter-Mediated nFCM Assay Platform for Quantifying Diverse Biochemical Analytes.

  Anal Chem, Mar 2026

• Characterization of Lymphocyte Subsets in Peripheral Blood of Patients with Colorectal Cancer.

  J Gastrointest Cancer, Feb 2026

• Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.

  Cell Oncol (Dordr), Feb 2026

• Single-cell mass cytometry reveals distinct immune signatures in colorectal cancer.

  Anal Methods, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.